The role of Social Capital in Education Literature: A Critical Synthesis

This critical synthesis incorporates both theoretical and empirical literature on social capital. A primary role of social capital is to enable a child to gain access to human, cultural, and economic capital, as well as to school resources and support. The focus of the review is on educational literature that studies social capital and educational equity. After outlining the approach, next, the study undertakes a critical review of the literature by first examining emphatical literature, trends in conceptualization, theoretical base, method and then assessing empirical support for claims that social capital is positively linked to education equity. Finally, discuss gaps in the conceptualization, measurement, and analysis of social cultural, economic and human capital in educational literature. Keywords: educational equity, literature reviews, social, economic, cultural and human capita

Impact of Managerial Perception of Intellectual Capital Disclosure Practices on the Credibility of the Financial Statements

This study aims to investigate the impact of managerial perception of intellectual capital disclosure practices on the credibility of the financial statements. As the method, the primary data was collected through a questionnaire. The targeted sample was the financial managers who are directly involved in preparing financial statements in the public limited companies. 150 questionnaires were distributed covering the financial managers in all the sectors using the stratified random sampling method. There were three hypotheses developed covering the major components of intellectual capital as human, customer and social. Correlation analysis was conducted to test the hypothesis using the SPSS software. It was found that there is a relationship between the managerial perception of intellectual capital disclosure practices and the credibility of the financial statements. Through a regression analysis, it showed that there is an impact of intellectual capital disclosure practices on the credibility of financial statements. The managers believe that the existing reporting practices do not represent the reality of the organizational performance until the intellectual capital is incorporated to the financial statements. Further, they have suggested that there should be a proper mechanism to report the intellectual capital in the financial statements or in the annual reports to avoid such kind of misrepresentation.KeywordsIntellectual Capital, Disclosure Practices, Credibility, Financial Statement

Meeting Triple Bottom Lines through Product Service Systems, Selling Purified Water Instead of Chemicals: An Extended Case Study

AbstractA Product-Service System (PSS) is an integrated product and service offering that delivers value in use. The purpose of this paper is to study the contribution of PSS to economic, social and environmental performance by changing the offering from product to product-service systems. The key attributes such as co-creation of value with customers, application of competences such as knowledge and skills on intangible resources are studied in depth in this case study. Authors have conducted a single-case study in order to achieve the aim of the paper. Analysis focuses on chemical supplier and the customer. Semi structured interviews were conducted to collect the primary data and supplementary data were used for theoretical triangulation (Jick, 1979; Yin, 2003; Baines et al., 2009). Deductive content analysis (Elo and Kyngäs, 2008) is conducted and findings were reported. By changing the business model of selling chemicals into selling purified water, the company has transformed from product focus to PSS focus. Both the customer and supplier were able to create value within and between systems. Customer acted as a co-creator of value. It has enhanced the triple bottom line by increasing the profit, reduced the environmental impact by reducing the chemical component and enhanced the employee morale and safety. This study creates the awareness about product service systems to enhance customer bonding, diminish competition and enhance triple bottom lines. This paper originates an empirical evidence of PSS in Sri Lanka and the economic, social and environmental benefits which can be derived thereby.Keywords: Product Service Systems, Triple Bottom Line, Sustainability, Servitization, Sri Lank

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

PROFITABILITY OF MOMENTUM AND CONTRARIAN STRATEGIES IN THE COLOMBO STOCK EXCHANGE (CSE)

This paper examines the profi tability of momentum and contrarian strategies in the Colombo Stock Exchange (CSE) around 1 to 12 months horizon covering the period from October 1991 to June 2005. We follow the same methodology of Jegadeesh and Titman (1993). The study fi nds that momentum strategies are highly profi table in the CSE. Examining between pre-and post-automation periods of the CSE, we fi nd evidence that momentum strategies are signifi cantly more profi table during post-automation period.Keywords: Momentum Strategies, Contrarian Strategies, Colombo Stock ExchangeFor full paper: [email protected]